Tag: Cancer: Lung
Plasma ctDNA Genotyping Can Accelerate Time to Treatment for NSCLC
Median time to treatment was 39 days for ACCELERATE cohort versus 62 days for reference cohort using standard tissue genotyping
Blood-Based Marker Plus PLCO Risk Model Can ID Lethal Lung Cancer
AUROC estimate of four-marker protein panel plus PLCOm2012 was 0.88 for risk prediction of lung cancer death
2019 to 2021 Saw Rise in Lung Cancer Screenings
Yet, variation in uptake seen by geography, race, smoking history, and age
Fewer Black Veterans Complete Referrals for Lung Cancer Screening
Black veterans had 34 percent lower odds of screening completion versus White veterans
Alectinib Exposure Lower With Low-Fat Yogurt Intake
More patients taking alectinib with low-fat yogurt do not reach the exposure threshold of 435 ng/mL
ASCO: Lack of Benefit Seen for Indefinite-Duration Immunotherapy in NSCLC
Lack of significant overall survival advantage seen for indefinite-duration versus fixed-duration immunotherapy
Surgical Treatment Provides Better Long-Term Survival for NSCLC
Findings seen compared with stereotactic body radiotherapy for early-stage disease
Cemiplimab + Chemotherapy Aids Quality of Life With Lung Cancer
Improvement seen compared with chemotherapy alone for first-line treatment of advanced non-small cell lung cancer
Quitting Smoking Early Linked to Lower Mortality After NSCLC Diagnosis
For ever smokers, log2-transformed years since smoking cessation before diagnosis associated with significantly lower mortality
Patient-Centered Approach Recommended for Oligometastatic NSCLC
Integration of definitive local therapy relevant if technically feasible and clinically safe to all disease sites
